FDA Adverse Event Injury Summary report: N

EPIC¿ VALVE (MITRAL)

MDR report key: 19097809 · Received April 12, 2024

Report

Report Number
2135147-2024-01668
Event Type
Injury
Date Received
April 12, 2024
Date of Event
March 15, 2024
Report Date
May 22, 2024
Manufacturer
ABBOTT MEDICAL
Product Code
LWR
PMA / PMN Number
P040021
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
IA, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

INVESTIGATION IS NOT YET COMPLETE. A FOLLOW-UP REPORT WILL BE SUBMITTED WITH ALL ADDITIONAL RELEVANT INFORMATION. LITERATURE ATTACHMENT: TRANSCATHETER MITRAL VALVE-IN-VALVE EXPLANT: LESSONS LEARNED.

Additional Manufacturer Narrative · 0

SUMMARIZED PATIENT OUTCOMES/COMPLICATIONS OF EPIC VALVE WAS REPORTED IN A RESEARCH ARTICLE IN A SUBJECT POPULATION WITH VON WILLEBRAND DISEASE. SOME OF THE COMPLICATIONS REPORTED WERE SURGICAL INTERVENTION (VALVE-IN-VALVE, SURGICAL EXPLANT), HOSPITALIZATION, MITRAL REGURGITATION, DYSPNEA AND MITRAL STENOSIS. A MORE COMPREHENSIVE ASSESSMENT COULD NOT BE PERFORMED AS THE EVENT WAS NON-CONTEMPORANEOUSLY REPORTED THROUGH A LITERATURE REVIEW AND NO DEVICE OR INDIVIDUAL PATIENT INFORMATION WAS RECEIVED FOR ANALYSIS.

Description of Event or Problem · 0

THE ARTICLE, "TRANSCATHETER MITRAL VALVE-IN-VALVE EXPLANT: LESSONS LEARNED", WAS REVIEWED. THE ARTICLE PRESENTED A CASE STUDY OF A 66-YEAR-OLD MALE PATIENT WITH VON WILLEBRAND DISEASE. IT WAS REPORTED THAT ON AN UNKNOWN DATE, A 29MM EPIC VALVE WAS IMPLANTED. IT WAS THEN REPORTED 10 YEARS POST-PROCEDURE ON AN UNKNOWN DATE, THE PATIENT PRESENTED WITH DYSPNEA DUE TO SEVERE MITRAL REGURGITATION. A DECISION WAS MADE TO PERFORM A TRANSCATHETER VALVE-IN-VALVE PROCEDURE WITH A 26MM SAPIEN VALVE. IT WAS THEN REPORTED ONE YEAR POST-INTERVENTION, THE PATIENT HAD ELEVATED GRADIENT. A DECISION WAS MADE TO SURGICALLY REMOVE BOTH 29MM EPIC VALVE WITH THE EMBEDDED 26MM SAPIEN VALVE. A 27/29 ON-X MECHANICAL VALVE WAS THEN IMPLANTED WITH NO ADVERSE PATIENT CONSEQUENCES. THE ARTICLE CONCLUDED THAT MITRAL VALVE-IN-VALVE EXPLANT IS TECHNICALLY FEASIBLE. THE AUTHORS RECOMMENDED EN BLOC REMOVAL OF BOTH VALVES AS THE SAFEST METHOD OF VALVE EXPLANT. [THE PRIMARY AND CORRESPONDING AUTHOR WAS MOHAMMAD BASHIR, UNIVERSITY OF IOWA CARVER COLLEGE OF MEDICINE, DEPARTMENT OF CARDIOTHORACIC SURGERY, IOWA CITY, IOWA 52242, WITH CORRESPONDING EMAIL: [email protected]]

Description of Event or Problem · 0

THE ARTICLE, "TRANSCATHETER MITRAL VALVE-IN-VALVE EXPLANT: LESSONS LEARNED", WAS REVIEWED. THE ARTICLE PRESENTED A CASE STUDY OF A 66-YEAR-OLD MALE PATIENT WITH VON WILLEBRAND DISEASE. IT WAS REPORTED THAT ON AN UNKNOWN DATE, A 29MM EPIC VALVE WAS IMPLANTED. IT WAS THEN REPORTED 10 YEARS POST-PROCEDURE ON AN UNKNOWN DATE, THE PATIENT PRESENTED WITH DYSPNEA DUE TO SEVERE MITRAL REGURGITATION. A DECISION WAS MADE TO PERFORM A TRANSCATHETER VALVE-IN-VALVE PROCEDURE WITH A 26MM SAPIEN VALVE. IT WAS THEN REPORTED ONE YEAR POST-INTERVENTION, THE PATIENT HAD ELEVATED GRADIENT. A DECISION WAS MADE TO SURGICALLY REMOVE BOTH 29MM EPIC VALVE WITH THE EMBEDDED 26MM SAPIEN VALVE. A 27/29 ON-X MECHANICAL VALVE WAS THEN IMPLANTED WITH NO ADVERSE PATIENT CONSEQUENCES. THE ARTICLE CONCLUDED THAT MITRAL VALVE-IN-VALVE EXPLANT IS TECHNICALLY FEASIBLE. THE AUTHORS RECOMMENDED EN BLOC REMOVAL OF BOTH VALVES AS THE SAFEST METHOD OF VALVE EXPLANT. [THE PRIMARY AND CORRESPONDING AUTHOR WAS MOHAMMAD BASHIR, UNIVERSITY OF IOWA CARVER COLLEGE OF MEDICINE, DEPARTMENT OF CARDIOTHORACIC SURGERY, IOWA CITY, IOWA 52242, WITH CORRESPONDING EMAIL: [email protected]].

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1509959 EPIC¿ VALVE (MITRAL) HEART-VALVE, NON-ALLOGRAFT TISSUE LWR ABBOTT MEDICAL

Patients

Seq Age Sex Outcome Treatment
1 66 YR Male Required Intervention| H